Abstract: The present invention relates to chimeric antigen receptor (CAR)-T cells, and particularly, although not exclusively, to their use in immunotherapy, and for treating, preventing or ameliorating cancer, such as T-cell lymphomas, various microbial infections, such as HIV and TB, and also autoimmune disease. The invention is especially concerned with the use of CAR-engineered mucosal-associated invariant T (MAIT) cells, and to novel methods for stimulating, isolating, and expanding highly purified MAIT cells, which can then be engineered into such CAR-MAIT cells. The invention is also concerned with methods for expansion of MAIT cells in vitro.

Abstract: The present invention relates to chimeric antigen receptor (CAR)-T cells, and particularly, although not exclusively, to anti-T-cell receptor (TCR) V-beta CARs, and to their use in immunotherapy, and for treating, preventing or ameliorating cancer, such as T-cell lymphomas, various microbial infections, such as HIV and TB, and also autoimmune disease. The invention is especially concerned with the use of CAR-engineered mucosal-associated invariant T (MAIT) cells, and to novel methods for stimulating, isolating and expanding highly purified MAIT cells, which can then be engineered into such CAR-MAIT cells. The invention extends to genetic constructs per se, and to their use in generating the CAR-MAIT cells, and to transduced CAR-MAIT cells per se. The invention also extends to various medical uses of the constructs and transduced CAR-MAIT cells, and to pharmaceutical compositions comprising these constructs and CAR-MAIT cells.

Abstract: The present invention relates to chimeric antigen receptor (CAR)-T cells, and particularly, although not exclusively, to anti-CD4 CARs, and to their use in immunotherapy, and for treating, preventing or ameliorating cancer, such as T-cell lymphomas, various microbial infections, such as HIV and TB, and also autoimmune disease. The invention is especially concerned with the use of CAR-engineered mucosal-associated invariant T (MAIT) cells, and to novel methods for stimulating, isolating and expanding highly purified MAIT cells, which can then be engineered into such CAR-MAIT cells. The invention extends to genetic constructs per se, and to their use in generating the CAR-MAIT cells, and to transduced CAR-MAIT cells per se. The invention also extends to various medical uses of the constructs and transduced CAR-MAIT cells, and to pharmaceutical compositions comprising these constructs and CAR-MAIT cells.

Abstract: A seawater desalination system is provided using a jet technique, which comprises a filter apparatus, a sonic energy treatment apparatus, and a desalination apparatus. After being coarse-filtered and fine-filtered, the seawater enters the sonic energy treatment apparatus. After being treated by the sonic energy treatment apparatus, the seawater is stored in a water storage tank in the form of small molecular clusters, and then pumped into a reverse osmosis membrane. After osmosis, the water becomes freshwater and stored in a freshwater tank. During the process, the reverse osmosis membrane can be replaced by a distillatory. The system has the advantages of a simple structure of the seawater desalination apparatus, less investment, low cost, and stable performance. The seawater is not only desalinated, but also chain-shortened into water of small molecular clusters, which is easily absorbed and utilized by human body.

Abstract: The invention provides immunocomplex comprising MHC molecules or functional fragments thereof which are modified so as to prevent binding to co-receptors e.g. CD8 or CD4. The inventors have determined that inability of the MHC complex to bind co-receptor leads to death of the T-cells without delivery of an activation/proliferation signal. By associating the immunocomplex with a specific peptide antigen it is possible to selectively suppress the immune system of a host, i.e. to help prevent tissue rejection or treat autoimmune diseases. For a more universal suppression of the immune system, it is possible to administer the modified MHC complex or fragment/component thereof in the absence of peptide antigen. For example, modified &bgr;M complex can be administered.